Evidence map›Paper›PMID 38035791›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024

Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States.

Seyed M Moghadas, Affan Shoukat, Carolyn E Bawden, Joanne M Langley, Burton H Singer, Meagan C Fitzpatrick, Alison P Galvani

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. [Recommendations on prevention and treatment of respiratory infections in institutionalised older people].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025
    Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Respiratory syncytial virus vaccination strategies for older Canadian adults: a cost-utility analysis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Seyed M MoghadasAgent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada.
Affan ShoukatAgent-Based Modelling Laboratory, York University, Toronto, Ontario, Canada.
Carolyn E BawdenDepartment of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada.
Joanne M LangleyCanadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, Nova Scotia, Canada.
Burton H SingerEmerging Pathogens Institute, University of Florida, Gainesville, Florida, USA.
Meagan C FitzpatrickCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Alison P GalvaniCenter for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, Connecticut, USA.
Yale University · USYork University · CAIzaak Walton Killam Health Centre · CAMcGill University · CAUniversity of Florida · US

Funding

Accelerating viral outbreak detection in US cities using mechanistic models, machine learning and diverse geospatial dataR01AI151176 · NIAID · YALE UNIVERSITY · PI GALVANI, ALISON P, MEYERS, LAUREN ANCEL · 2020 to 2024
$3.9M
Mathematical modeling to optimize rotavirus vaccination in sub-Saharan AfricaK01AI141576 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI FITZPATRICK, MEAGAN COLLEEN · 2019 to 2023
$649k
NIAID NIH HHS K01 AI141576NIAID NIH HHS R01 AI151176NIH HHS 5 K01 AI141576NIH HHS R01 AI151176)NSERC 576914-22NSF Expeditions 1918784)The Notsew Orm Sands Foundation
6 · The paper itself

Abstract

backgroundTwo prefusion F protein-based vaccines, Arexvy and Abrysvo, have been authorized by the US Food and Drug Administration for protecting older adults against respiratory syncytial virus (RSV)-associated lower respiratory tract illness. We evaluated the health benefits and cost-effectiveness of these vaccines.

methodsWe developed a discrete-event simulation model, parameterized with the burden of RSV disease including outpatient care, hospitalization, and death for adults aged 60 years or older in the United States. Taking into account the costs associated with these RSV-related outcomes, we calculated the net monetary benefit using quality-adjusted life-year (QALY) gained as a measure of effectiveness and determined the range of price-per-dose (PPD) for Arexvy and Abrysvo vaccination programs to be cost-effective from a societal perspective.

resultsUsing a willingness-to-pay of $95 000 per QALY gained, we found that vaccination programs could be cost-effective for a PPD up to $127 with Arexvy and $118 with Abrysvo over the first RSV season. Achieving an influenza-like vaccination coverage of 66% for the population of older adults in the United States, the budget impact of these programs at the maximum PPD ranged from $6.48 to $6.78 billion. If the benefits of vaccination extend to a second RSV season as reported in clinical trials, we estimated a maximum PPD of $235 for Arexvy and $245 for Abrysvo, with 2-year budget impacts of $11.78 and $12.25 billion, respectively.

conclusionsVaccination of older adults would provide substantial direct health benefits by reducing outcomes associated with RSV-related illness in this population.

Indexed as

Cost-Benefit AnalysisQuality-Adjusted Life YearsRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAgedAged, 80 and overFemaleHumansMaleMiddle AgedRespiratory Syncytial Virus, HumanUnited StatesVaccinationViral Fusion ProteinsRespiratory Syncytial Virus VaccinesViral Fusion Proteinscost-effectivenessolder adultsRSVsimulationvaccination

Identifiers

PMID38035791
PMCPMC11093660
OpenAlexW4389209882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.